Scivision BiotechTPE:1786 -0.56%80 EV-to-FCF is 150.48 as of Jul. 09, 2026, which is 424% above its 10-year median of 28.74. GuruFocus rates TPE:1786 with a GF Score™ of 80/100 and a GF Value™ of NT$115.23 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 414 Medical Devices & Instruments companies, Scivision Biotech ranks worse than 89.86% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Scivision Biotech's Enterprise Value is NT$3,345.5 Mil.
Scivision Biotech's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was NT$22.2 Mil. Therefore, Scivision Biotech's EV-to-FCF for today is 150.48.
The historical rank and industry rank for Scivision Biotech's EV-to-FCF or its related term are showing as below:
TPE:1786'
s EV-to-FCF Range Over the Past 10 Years
Min: -507.39 Med: 28.74 Max: 340.17
Current: 153.12
During the past 13 years, the highest EV-to-FCF of Scivision Biotech was 340.17. The lowest was -507.39. And the median was 28.74.
TPE:1786's EV-to-FCF is ranked worse than 89.86% of 414
companies
in the Medical Devices & Instruments industry
Industry Median: 23.005
vs TPE:1786: 153.12
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Scivision Biotech's PE Ratio (TTM) for today is calculated as:
Scivision Biotech's share price for today is NT$53.50.
Scivision Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$2.150.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Scivision Biotech EV-to-FCF Related Terms
Scivision Biotech EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Scivision Biotech's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Scivision Biotech's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scivision Biotech EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Scivision Biotech's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Scivision Biotech's EV-to-FCF falls into.
Scivision Biotech's current Enterprise Value is NT$3,345.5 Mil.
Scivision Biotech's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$22.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scivision Biotech (TPE:1786) has a EV-to-FCF of 150.48 as of Jul. 09, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Scivision Biotech and its competitors. This is 424% above median its historical median of 28.74. According to the industry distribution chart, Scivision Biotech ranks #372 out of 414 companies in the Medical Devices & Instruments industry, placing it in the top 89.9%.
Is Scivision Biotech's EV-to-FCF too high?
Scivision Biotech's current EV-to-FCF of 150.48 is 424% above median its 10-year median of 28.74. The Medical Devices & Instruments industry median EV-to-FCF is 23.01. Scivision Biotech's value of 150.48 is 554.1% above this industry median. Based on the distribution chart, Scivision Biotech ranks #372 out of 414 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Scivision Biotech has a GF Score™ of 80/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Scivision Biotech's EV-to-FCF compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Scivision Biotech ranks #372 out of 414 companies for EV-to-FCF. This places Scivision Biotech in the lower half of its industry. The industry median EV-to-FCF is 23.01. Scivision Biotech's value of 150.48 is 554.1% above this benchmark. While the company's 10-year median is 28.74 vs. the industry median of 23.01, Scivision Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 23.01, based on 414 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Scivision Biotech's current EV-to-FCF of 150.48 is 554.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Scivision Biotech and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 23.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Scivision Biotech's current EV-to-FCF is 150.48, which is 424% above median its own 10-year median of 28.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scivision Biotech stock overvalued right now?
Based on GuruFocus' analysis, Scivision Biotech (TPE:1786) is currently considered Possible Value Trap. The stock's GF Value™ is NT$115.23, compared to a current price of NT$53.50 — trading 53.6% below its estimated fair value. The current EV-to-FCF is 150.48, which is 424% above median its 10-year median of 28.74 and 554.1% above the Medical Devices & Instruments industry median of 23.01. Scivision Biotech's overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Scivision Biotech (TPE:1786), the current EV-to-FCF is 150.48 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Scivision Biotech (TPE:1786) Overvalued in 2026?
Based on GuruFocus' analysis, Scivision Biotech stock appears to be undervalued.
The current stock price of NT$53.50 is trading 53.6% below its estimated GF Value™ of NT$115.23.
GuruFocus considers Scivision Biotech to be Possible Value Trap.
Key valuation signals for TPE:1786:
EV-to-FCF: 150.48 (424% above median its 10-year median of 28.74)
GF Value™: NT$115.23 vs. price of NT$53.50 (53.6% below fair value)
Industry Position: 554.1% above the Medical Devices & Instruments median (#372 of 414)
No single metric tells the full story. See the TPE:1786 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Scivision Biotech Inc is engaged in the manufacturing and distribution of hyaluronic acid medical supplies in Taiwan. It offers medical devices, including absorbable adhesion barriers, dermal implants, synovial fluid supplements, and intravesical instillation.
80GF Score
Get the complete analysis for TPE:1786
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1786 has been successfully added to your 
